Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition episode artwork

EPISODE · May 6, 2024 · 1H 7M

Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition

from Oncology Today with Dr Neil Love

Dr Matthew D Galsky from Icahn School of Medicine at Mount Sinai in New York, New York, summarizes treatment options for patients with HER2-altered genitourinary cancers and reviews recent emerging clinical trial data in the field, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here.

Episode metadata supplied by the publisher feed · Published May 6, 2024

Embed this episode

Ready to play

Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition

0:00 1:07:29

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Oncology Today with Dr Neil Love?

This episode is 1 hour and 7 minutes long.

When was this Oncology Today with Dr Neil Love episode published?

This episode was published on May 6, 2024.

Can I download this Oncology Today with Dr Neil Love episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!